Journal of Geriatric Psychiatry and Neurology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knesper, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knesper, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Geriatric Psychiatry and Neurology, Vol. 8, No. 1, S40-S51 (1995)
DOI: 10.1177/089198879500800106

The Depressions of Alzheimer's Disease: Sorting, Pharmacotherapy, and Clinical Advice

David J. Knesper, MD

Research describing wide prevalence variation of Alzheimer's disease (AD) and comorbid depression is explained in light of subsyndromal depressions, the use of standardized diagnostic instruments and procedures, and the subcortical and cortical components of mood. There appear to be several "depressions" of AD. Against this backdrop, double-blind, placebo-controlled studies of antidepressant use in AD are reviewed and methodologic problems identified. Evidence for efficacy in controlled trials is weak, but open-label trials are, as expected, more encouraging. The potential efficacy of new agents for the depressions of AD receive comment. A heuristic model makes use of the conclusions developed, the stage of illness, and a preliminary classification scheme for the depressions of AD; this model provides a rational basis for thinking about medication selection for AD depressions. Clinical decisions are illustrated. (J Geriatr Psychiatry Neurol 1995; 8(suppl 1):S40-S51).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
D. T. Villareal, E. Grant, J. P. Miller, M. Storandt, D. W. McKeel, and J. C. Morris
Clinical outcomes of possible versus probable Alzheimer's disease
Neurology, September 9, 2003; 61(5): 661 - 667.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
A. Perrault, M. Oremus, L. Demers, S. Vida, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales
J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 181 - 196.
[Abstract] [PDF]